Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 1997

Primary Completion Date

July 8, 1998

Study Completion Date

July 8, 1998

Conditions

Juvenile Rheumatoid Arthritis

Interventions

DRUG

Etanercept

Administered twice weekly by subcutaneous injection

DRUG

Placebo

Administered twice weekly by subcutaneous injection